The U.S. Food and Drug Administration granted accelerated approval to Ascendis Pharma’s TransCon CNP (now Yuviwel/navepegritide) for children two and older with achondroplasia, based on gains in annualized growth velocity (AGV). Ascendis received a rare pediatric disease priority review voucher with the approval and expects to make the drug available through prescribing physicians in Q2. Yuviwel’s once‑weekly dosing positions it against BioMarin’s daily Voxzogo; analysts predict modest 2026 uptake with potential expansion in 2027 and a planned EU decision later this year. Ascendis must complete confirmatory trials to maintain approval under the accelerated pathway, and pricing and market share dynamics in this small patient population will determine long‑term commercial performance.